James Tankel
@JamieTankel
Followers
211
Following
150
Media
5
Statuses
253
General surgery residency, Shaare Tzedek, Jerusalem. Fellow in thoracic and upper GI surgery @ McGill
Québec, Canada
Joined June 2022
RT @PalSanjima: 📣 Excited to share our lab's latest preprint, detailing a comprehensive study on longitudinally collected GEA patient-deriv….
0
3
0
RT @LFerri123: So excited to see this paper on the stromal changes driving Barrett’s Esophagus progression to Cancer. A Herculean effort ef….
0
14
0
RT @ElliotServaisMD: Join us Wednesday, July 16, for “Best of Esophageal” highlights from the @AATSHQ 2025 annual meeting!. .
0
14
0
Kinda neat technique. never seems to be a good way to manage these patients so good to have another approach in the tool box!.
@EndoCollabcom Full publication here!
0
1
3
Whoever is in Montreal, I strongly suggest attending this meeting. rubbing shoulders with leaders in the Mx on lung cancer.
Nous avons le plaisir d’annoncer la troisième édition de la conférence internationale intitulée « Early-stage Lung cancer International eXpert Retreat » — #ELIXR25, une collaboration du Centre universitaire de santé McGill (Dr Jonathan Spicer) et du Centre hospitalier de
0
0
1
Guess that means I'm off to Australia for a couple of days ! . See you there @LFerri123 @MagnusNsurgonc @MarkarSheraz
2
1
12
RT @DoctorJSpicer: It seems we are in a bit of a data quagmire. I often get asked how to choose between neoadjuvant versus perioperative im….
0
21
0
This is the data that many of us have been waiting for. Whilst exciting, epoch changing it is not. should we be focusing on personalising care rather than still trying to make a square peg fit a round hole?.
Presented at #ASCO25: . In resectable gastric and gastroesophageal junction cancer, adding durvalumab to perioperative chemotherapy improved event-free survival and pathological complete response, with no major increase in high-grade adverse events. Full MATTERHORN trial
0
0
0
This is a really important document, helping to guide surgeons how to manage these challenging cases. maybe it could be followed by a technical paper exploring aspects of redo surgery ?.
Hot off the press! . "International Society for Diseases of the Esophagus consensus on management of the failed fundoplication". #GERD #SoMe4Surgery #ISDE #EsophagealSurgery.
0
3
7
RT @DOTEsophagus: Hot off the press! . "International Society for Diseases of the Esophagus consensus on management of the failed fundoplic….
0
11
0
Don't let it pass under the radar!. Organ chip is hugely important in eso cancer where the complex immuno-environment is making the implementation of immunotherapy challenging! . This research will help unravel that. Hugely talented team @MThoracics. @PalSanjima @LFerri123.
Great seeing this manuscript in print on patient-specific esophagus cancer-organ chip. Complete clinical mimicry Excellent work by @PalSanjima @RIMUHC1 with collaboration with @wyssinstitute @DonIngber
0
2
4
RT @LFerri123: Great seeing this manuscript in print on patient-specific esophagus cancer-organ chip. Complete clinical mimicry Excellent w….
translational-medicine.biomedcentral.com
Background Esophageal adenocarcinoma (EAC) is the sixth most deadly cancer worldwide, with increasing incidence in North America. As no targeted therapy or immunotherapy has revolutionized the...
0
6
0
I'm not sure where else in medicine we would call a 30% failure rate at 1 year a 'safe alternative' approach.
thelancet.com
This meta-analysis showed that antibiotic treatment in adults with imaging-confirmed acute appendicitis was a safe alternative to surgery and resulted in around two-thirds of patients avoiding...
0
0
5
RT @MarkarSheraz: Great to see this published. We need to consider the physical strain on operating surgeons as a core endpoint to the eval….
0
4
0
Was quite touched to be asked to write this for @ASCO. Has immunotherapy put the nail in the coffin for oligometastatic SCC? . Have a read and decide!.@JonathanCools.
dailynews.ascopubs.org
Synchronous oligometastatic esophageal squamous cell carcinoma is an uncommon disease, with a limited evidence base supporting the ideal treatment approach. Although multimodal treatment with local...
1
1
12
Tons of information in this study + needs a careful read. Low rate of major comps and impressive length of stay *bbuutt* 50% of Obesity class III were ASA I/II, 93% had open surgery, 70% no fundo & x2 as many minor comps. Maybe high BMI should trigger a case-by-case approach?.
Does body mass index impact outcomes after paraoesophageal hernia repair? Check out this paper from Drs Han and Low evaluating this question - now available open access in Diseases of the Esopghagus. #OpenAccess #SoMe4Surgery.
0
0
2